Charleston, SC, United States of America

Craig Cano Beeson

USPTO Granted Patents = 12 (Patent Applications = 8)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 3.6

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

12 out of 173

Musc Foundation for Research Development

patents

2 out of 889

The United States Government As Represented by the Department of Veterans Affairs

patents

where one patent can have more than one assignee

Years Active: 2008-2024

Loading Chart...

12 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11939301 - 5HT1F receptor agonists and mitochondrial biogenesis (2024-03-26),

2. 11014892 - 5HT1F receptor agonists and mitochondrial biogenesis (2021-05-25),

3. 10456400 - Aza-ellipticine analogs, methods of synthesis and methods of treatment (2019-10-29),

4. 10370328 - Oxindole compounds and pharmaceutical compositions thereof (2019-08-06),

5. 9981994 - Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders (2018-05-29),

6. 9970947 - Fluorescent probe (2018-05-15),

7. 9920029 - Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders (2018-03-20),

8. 9850218 - Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders (2017-12-26),

9. 9556207 - Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders (2017-01-31),

10. 9079853 - Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders (2015-07-14),

11. 8921401 - Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders (2014-12-30),

12. 7423025 - L-nucleosides as ligands to adenosine receptors (2008-09-09),

Title: The Innovations of Craig Cano Beeson

Introduction

Craig Cano Beeson is a notable inventor based in Charleston, SC, with a significant contribution to the field of pharmaceutical sciences. He holds a total of 12 patents, showcasing his innovative spirit and dedication to advancing medical treatments. His work primarily focuses on compounds that promote mitochondrial biogenesis, which are crucial for treating various kidney-related ailments.

Latest Patents

Among his latest patents are the 5HT1F receptor agonists and mitochondrial biogenesis. These patents detail compounds of a specific formula, along with their pharmaceutically acceptable salts. The compounds are designed to promote mitochondrial biogenesis and are particularly useful in treating conditions such as acute kidney injury and chronic kidney disease. This innovative approach highlights his commitment to addressing critical health issues through scientific research.

Career Highlights

Throughout his career, Craig has worked with esteemed organizations, including the MUSC Foundation for Research Development and the United States Government as represented by the Department of Veterans Affairs. His experience in these institutions has allowed him to contribute significantly to research and development in the medical field.

Collaborations

Craig has collaborated with notable colleagues, including Christopher C Lindsey and Yuri Karl Peterson. These partnerships have further enriched his research endeavors and have led to advancements in his field.

Conclusion

Craig Cano Beeson exemplifies the spirit of innovation in the pharmaceutical industry. His contributions through patents and collaborations have the potential to make a significant impact on medical treatments for kidney diseases. His work continues to inspire future advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.